Profiling immune cells to understand responses to melanoma treatment
Phenotypic, Functional, Metabolic and Transcriptomic Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
University Hospital, Grenoble · NCT06154668
This study is trying to see how a specific cancer treatment affects the immune system in melanoma patients to help find better ways to personalize their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 707 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble (other) |
| Locations | 1 site (Grenoble) |
| Trial ID | NCT06154668 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate how anti-PD1 immunotherapy affects the immune system in melanoma patients by analyzing the characteristics and responses of circulating immune cells. The focus is on identifying biomarkers that predict patient responses to treatment, which could help tailor therapies to individual needs. By examining the phenotypic, functional, metabolic, and transcriptomic profiles of immune cells, the study seeks to enhance understanding of treatment efficacy and adverse effects. The research will involve both retrospective and prospective components, depending on patient consent.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed melanoma at any stage (I, II, III, or IV) who can provide informed consent.
Not a fit: Patients with ocular melanoma or those under legal protection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for melanoma patients undergoing anti-PD1 therapy.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for immunotherapy responses, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with histologically confirmed melanoma (stage I, II, III or IV based on AJCC classification) * Able to sign the informed collection consent for the retrospective part or to express their non-opposition to the research for the prospective part of the study Exclusion Criteria: * Subject under guardianship or subject deprived of freedom * Persons benefiting from special protection (as defined in Articles L1121-5 and L1121-8 of the Public Health Code): minors, pregnant or breastfeeding women, adults protected by law (under guardianship, curatorship or deprived of liberty) and persons hospitalized without their consent (as defined in Articles L3212-1 and L3212-3 of the Public Health Code). * ocular melanoma
Where this trial is running
Grenoble
- CHU Grenoble Alpes — Grenoble, France (RECRUITING)
Study contacts
- Principal investigator: Julie Charles, MD, PhD — CHU Grenoble Alpes
- Study coordinator: Julie Charles, MD, PhD
- Email: jcharles@chu-grenoble.fr
- Phone: 476769320
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Melanoma